Impact of direct-acting antivirals on de novo occurrence of hepatocellular carcinoma in hepatitis C virus patients

Abstract

Hepatitis C Virus (HCV) infection constitutes a significant burden to world health, leading to liver cirrhosis and hepatocellular carcinoma (HCC). In the past decades, pegylated interferon combined with ribavirin has been used extensively for HCV treatment, and interferon (IFN) is thought to have antitumor property. Direct-acting antivirals (DAAs) have fundamentally changed HCV therapy, due to their high efficacy and tolerability. However, recent studies have reported relatively high rates of HCC occurrence, and recurrence, following successful HCV treatment using DAAs. These studies were grossly underpowered due to their retrospective design, lack of untreated or IFN controls, small sample size, and limited patient follow-up time. From then, many retrospective and prospective cohort studies with larger size and longer follow-up duration after DAAs therapy have been published. These studies showed that treatment with DAAs can reduce the risk of HCC compared to no treatment, didn’t increase the risk of HCC compared to IFN-based therapy after adjusting for the potential confounders of these two groups, and DAAs-induced sustained virological response decreased the risk of HCC compared to DAAs treatment failure. In conclusion, DAAs treatment doesn’t appear to increase the development of HCC, even in cirrhotic patients. However, cirrhotic patients should be monitored for the development of HCC during and after DAAs treatment.

Keywords

Sustained virological response / hepatocellular carcinoma / liver cirrhosis

References

[1] World Health Organization. Hepatitis C. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c [Last accessed on 18 May 2020]

[2] El-Serag HB.Hepatocellular carcinoma..N Engl J Med2011;365:1118-27

[3] Fried MW,Reddy KR,Marinos G.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection..N Engl J Med2002;347:975-82

[4] Morgan RL,Smith BD,Pitasi M.Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies..Ann Intern Med2013;158:329-37

[5] Bruno S,Colombo M,Benvegnù L.Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study..Hepatology2007;45:579-87

[6] Cardoso AC,Figueiredo-Mendes C,Giuily N.Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis..J Hepatol2010;52:652-7

[7] Curry MP,Bzowej N,Korenblat KM.Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis..N Engl J Med2015;373:2618-28

[8] Foster GR,Cheung MC,Hudson BE.Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis..J Hepatol2016;64:1224-31

[9] Crespo G,Londoño MC,Baliellas C.The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition..J Hepatol2018;69:11-7

[10] Reig M,Perelló C,Ribeiro A.Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy..J Hepatol2016;65:719-26

[11] Conti F,Scuteri A,Bolondi L.Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals..J Hepatol2016;65:727-33

[12] Cardoso H,Rodrigues S,Albuquerque A.High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis..J Hepatol2016;65:1070-1

[13] Kozbial K,Schwarzer R,Al-Zoairy R.Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment..J Hepatol2016;65:856-8

[14] Ravi S,Jones D,Simpson H.Unusually high rates of hepatocellular carcinoma after treatment with direct-acting antiviral therapy for hepatitis C related cirrhosis..Gastroenterology2017;152:911-2

[15] Serti E,Kim YJ,Fryzek N.Successful interferon-free therapy of chronic hepatitis C virus infection normalizes natural killer cell function..Gastroenterology2015;149:190-200.e2 PMCID:PMC4523392

[16] Meissner EG,Osinusi A,Virtaneva K.Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome..J Clin Invest2014;124:3352-63 PMCID:PMC4109554

[17] Tsai WC,Lai TC,Lin CW.MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma..Hepatology2009;49:1571-82

[18] Waring JF,Abel S,Cohen DE.Serum miR-122 may serve as a biomarker for response to direct acting antivirals: effect of paritaprevir/R with dasabuvir or ombitasvir on miR-122 in HCV-infected subjects..J Viral Hepat2016;23:96-104

[19] Debes JD,Groothuismink ZMA,Schulze Zur Wiesch J.Levels of cytokines in serum associate with development of hepatocellular carcinoma in patients with HCV infection treated with direct-acting antivirals..Gastroenterology2018;154:515-517.e3

[20] Cheung MCM,Hudson BE,McLauchlan J.Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis..J Hepatol2016;65:741-7

[21] Nagata H,Asahina Y,Asano Y.Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C..J Hepatol2017;67:933-9

[22] Kanwal F,Asch SM,Cao Y.Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents..Gastroenterology2017;153:996-1005.e1

[23] Ioannou GN,Berry K.HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma..J Hepatol2017;25-32 PMCID:PMC5837901

[24] Singer AW,Telep LE,Brainard DM.Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study..Aliment Pharmacol Ther2018;47:1278-87

[25] Innes H,Hayes PC,Dillon JF.The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen..J Hepatol2018;68:646-54

[26] Li DK,Fierer DS,Shaikh OS.The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: an ERCHIVES study..Hepatology2018;67:2244-53

[27] Romano A,Piovesan S,Anastassopoulos G.Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study..J Hepatol2018;69:345-52

[28] Nahon P,Bourcier V,Marcellin P.Incidence of hepatocellular carcinoma after direct antiviral therapy for HCV in patients with cirrhosis included in surveillance programs..Gastroenterology2018;155:1436-50.e6

[29] Calvaruso V,Cacciola I,Madonia S.Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents..Gastroenterology2018;155:411-21.e4

[30] Lleo A,Aghemo A,Bruno S.Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals..Dig Liver Dis2019;51:310-7

[31] Mettke F,Deterding K,Smith A.Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis..Aliment Pharmacol Ther2018;47:516-25

[32] Carrat F,Dorival C,Diallo A.Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study..Lancet2019;393:1453-64

[33] Backus LI,Shahoumian TA.Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease..Hepatology2019;69:487-97

[34] Buonomo AR,Coppola C,Viceconte G.Direct acting antivirals treatment for hepatitis C virus infection does not increase the incidence of de novo hepatocellular carcinoma occurrence: Results from an Italian real-life cohort (LINA cohort)..Medicine (Baltimore)2020;99:e18948 PMCID:PMC7015572

[35] Colussi G,Brizzi RF,Valenti L.Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: a retrospective study..World J Gastroenterol2019;25:6094-106 PMCID:PMC6824275

[36] Ebel F,Port K,Manns MP.Letter: a 5-year long-term follow-up study after DAA treatment confirms a reduced HCC risk in a central European cohort of HCV patients with liver cirrhosis..Aliment Pharmacol Ther2020;51:194-5

[37] Kanwal F,Asch SM,Li L.Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents..Hepatology2020;71:44-55

[38] Ide T,Nakano M,Yatsuhashi H.Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study..Hepatol Int2019;13:293-301

[39] Ioannou GN,Green PK,Tapper EB.Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores..Gastroenterology2019;157:1264-78.e4 PMCID:PMC6815714